Figures & data
Table 1 Comparison of Clinical and Laboratory Characteristics at Baseline and the 12th Month Between Lipid-Lowering Group and Control Group
Figure 1 Decrease trends of transaminases and blood lipids in the lipid-lowering group (n = 325) and control group (n = 216). Repeated-measures analysis of variance (ANOVA) for the comparison of effects on ALT (A), AST (B), GGT (C), total cholesterol (D), triglyceride (E), and LDL-c (F) between lipid-lowering group and control group. P values were for the ANOVA analysis between the two groups.
![Figure 1 Decrease trends of transaminases and blood lipids in the lipid-lowering group (n = 325) and control group (n = 216). Repeated-measures analysis of variance (ANOVA) for the comparison of effects on ALT (A), AST (B), GGT (C), total cholesterol (D), triglyceride (E), and LDL-c (F) between lipid-lowering group and control group. P values were for the ANOVA analysis between the two groups.](/cms/asset/f2e53c67-a474-4219-8be5-c68b15e44c9b/dmso_a_356371_f0001_c.jpg)
Figure 2 Correlation analysis between changes in transaminase and blood lipids in the lipid-lowering group (n = 325) and control group (n = 216). ***P < 0.001, **P < 0.01. *P < 0.05.
![Figure 2 Correlation analysis between changes in transaminase and blood lipids in the lipid-lowering group (n = 325) and control group (n = 216). ***P < 0.001, **P < 0.01. *P < 0.05.](/cms/asset/8493930c-e7de-49bf-b504-302cbed667fb/dmso_a_356371_f0002_c.jpg)
Figure 3 The impact of declining blood lipid levels on transaminase and GGT normalization. Comparison of transaminase and GGT normalization rate between the lipid-lowering group (n = 325) and control group (n = 216) (A), statin group (n = 216) and fibrate group (n = 91) (B and C), MAFLD with T2DM group (n = 67) and without T2DM group (n = 258), the male group (n = 241) and female group (n = 84) (C), and groups of 3 different reduction ranges in blood lipids (G). Comparison of LDL-c (D) and non-HDL-c (E) treated to target rate between the lipid-lowering group and the control group. Comparison of reduction ranges in blood lipids between the transaminase and GGT normalization group (n = 169) and nonnormalized group (n = 156) (F). ***P < 0.001, *P < 0.05.
![Figure 3 The impact of declining blood lipid levels on transaminase and GGT normalization. Comparison of transaminase and GGT normalization rate between the lipid-lowering group (n = 325) and control group (n = 216) (A), statin group (n = 216) and fibrate group (n = 91) (B and C), MAFLD with T2DM group (n = 67) and without T2DM group (n = 258), the male group (n = 241) and female group (n = 84) (C), and groups of 3 different reduction ranges in blood lipids (G). Comparison of LDL-c (D) and non-HDL-c (E) treated to target rate between the lipid-lowering group and the control group. Comparison of reduction ranges in blood lipids between the transaminase and GGT normalization group (n = 169) and nonnormalized group (n = 156) (F). ***P < 0.001, *P < 0.05.](/cms/asset/45376ed5-9fe3-4b0e-8bd2-d0ccd64e2977/dmso_a_356371_f0003_c.jpg)
Table 2 Univariate and Multivariate Analyses of Factors Associated with Transaminase and GGT Normalization by Lipid-Lowering Agents